Shares of Tyme Technologies Inc. (NASDAQ:TYME), buoyed earlier this week on anticipation of new data for its lead program, SM-88, fell 35.4 percent to $2.41 on Friday as results of an open-label phase II study in heavily pretreated pancreatic cancer drew mixed reactions. Criticism over the company's headline claim of "improved survival" and questions about the drug's efficacy dominated commentary on Twitter, while analysts following the company seemed to see a brighter picture in a bleak indication, third-line therapy.